000168080 001__ 168080
000168080 005__ 20240229133556.0
000168080 0247_ $$2doi$$a10.1093/ajcn/nqaa405
000168080 0247_ $$2pmid$$apmid:33740035
000168080 0247_ $$2ISSN$$a0002-9165
000168080 0247_ $$2ISSN$$a0095-9871
000168080 0247_ $$2ISSN$$a1938-3207
000168080 0247_ $$2ISSN$$a1938-3215
000168080 0247_ $$2altmetric$$aaltmetric:102139829
000168080 037__ $$aDKFZ-2021-00668
000168080 041__ $$aEnglish
000168080 082__ $$a570
000168080 1001_ $$0P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aBoakye, Daniel$$b0$$eFirst author$$udkfz
000168080 245__ $$aThe association of vitamin D with survival in colorectal cancer patients depends on antioxidant capacity.
000168080 260__ $$aOxford$$bOxford University Press$$c2021
000168080 3367_ $$2DRIVER$$aarticle
000168080 3367_ $$2DataCite$$aOutput Types/Journal article
000168080 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625054213_24032
000168080 3367_ $$2BibTeX$$aARTICLE
000168080 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168080 3367_ $$00$$2EndNote$$aJournal Article
000168080 500__ $$a#EA:C070#LA:C070# / 113(6):1458-1467
000168080 520__ $$aVitamin D plays a role in detoxifying free radicals, which might explain the previously reported lower mortality in colorectal cancer (CRC) patients with higher vitamin D concentrations.We aimed to assess whether the associations of 25-hydroxyvitamin D [25(OH)D] with prognosis in CRC patients differ by total thiol concentration (TTC), a biomarker of antioxidant capacity.CRC patients who were diagnosed from 2003 to 2010 and recruited into a population-based study in southern Germany (n = 2,592) were followed over a period of 6 y. 25(OH)D and TTC were evaluated from blood samples collected shortly after CRC diagnosis. Associations of 25(OH)D with all-cause and CRC mortality according to TTC were estimated using multivariable Cox proportional hazards regression.There was a weak positive correlation between 25(OH)D and TTC (r = 0.26, P < 0.001). 25(OH)D was inversely associated with mortality among patients in the lowest and middle TTC tertiles, but no associations were found among patients in the highest TTC tertile (P-interaction = 0.01). Among patients in the lowest/middle TTC tertiles, those in the middle and highest (compared with lowest) 25(OH)D tertiles had 31% and 44% lower all-cause mortality (P < 0.001) and 25% and 45% lower CRC mortality (P < 0.001), respectively. However, in the highest TTC tertile, 25(OH)D was not associated with all-cause (P = 0.638) or CRC mortality (P = 0.395).The survival advantages in CRC patients with adequate vitamin D strongly depend on antioxidant capacity and are most pronounced in cases of low antioxidant capacity. These findings suggest that TTC and other biomarkers of antioxidant status may be useful as the basis for enhanced selection criteria of patients for vitamin D supplementation, in addition to the conventional judgment based on blood 25(OH)D concentrations, and also for refining selection of patients for clinical trials aiming to estimate the effect of vitamin D supplementation.
000168080 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000168080 588__ $$aDataset connected to CrossRef, PubMed,
000168080 650_7 $$2Other$$a25(OH)D
000168080 650_7 $$2Other$$aantioxidant capacity
000168080 650_7 $$2Other$$acolorectal cancer
000168080 650_7 $$2Other$$asurvival
000168080 650_7 $$2Other$$atotal thiol
000168080 650_7 $$2Other$$avitamin D
000168080 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000168080 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b2$$udkfz
000168080 7001_ $$aJansen, Eugene H J M$$b3
000168080 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b4$$udkfz
000168080 7001_ $$0P:(DE-He78)9ea669c4d6a0d766d229d81c1819797d$$aMaalmi, Haifa$$b5
000168080 7001_ $$0P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aGao, Xin$$b6$$udkfz
000168080 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b7$$udkfz
000168080 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$udkfz
000168080 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$eLast author$$udkfz
000168080 773__ $$0PERI:(DE-600)1496439-9$$a10.1093/ajcn/nqaa405$$gp. nqaa405$$n6$$p1458-1467$$tThe American journal of clinical nutrition$$v113$$x1938-3207$$y2021
000168080 909CO $$ooai:inrepo02.dkfz.de:168080$$pVDB
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9ea669c4d6a0d766d229d81c1819797d$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000168080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000168080 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000168080 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000168080 9141_ $$y2021
000168080 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J CLIN NUTR : 2019$$d2021-02-02
000168080 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bAM J CLIN NUTR : 2019$$d2021-02-02
000168080 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000168080 9201_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x1
000168080 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000168080 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x3
000168080 980__ $$ajournal
000168080 980__ $$aVDB
000168080 980__ $$aI:(DE-He78)C070-20160331
000168080 980__ $$aI:(DE-He78)D240-20160331
000168080 980__ $$aI:(DE-He78)C020-20160331
000168080 980__ $$aI:(DE-He78)C120-20160331
000168080 980__ $$aUNRESTRICTED